^
    Back
    Association details:
    Biomarker:BRAF V600R
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Excerpt:
    One patient each with BRAF K601E and BRAF V600R had prolonged PR.
    DOI:
    10.1200/JCO.2012.43.5966
    Trial ID:
    NCT01037127